Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB is an international biopharmaceutical company headquartered in Stockholm, Sweden, specializing in treatments for rare diseases within haematology, immunology, and specialty care. It focuses on researching, developing, manufacturing, and commercializing innovative therapies for conditions such as haemophilia, immune thrombocytopenia (ITP), cryopyrin-associated periodic syndromes (CAPS), respiratory syncytial virus (RSV) in infants, and hemophagocytic lymphohistiocytosis (HLH). Key products include Elocta and Alprolix for haemophilia, Doptelet for ITP and chronic liver disease, Kineret for autoinflammatory disorders, Synagis for RSV prevention, and Gamifant for primary HLH. The company maintains a robust pipeline with investigational therapies targeting paroxysmal nocturnal hemoglobinuria (PNH), secondary HLH, acute graft failure, ALS, chronic refractory gout, and notably pozdeutinurad (AR882) for gout following the 2025 acquisition of Arthrosi Therapeutics. Originating from mergers in the early 2000s and the 2010 acquisition of Swedish Orphan International, Swedish Orphan Biovitrum AB plays a vital role in addressing unmet needs in orphan and specialty medicines, serving patients globally through partnerships and its own operations.